



Idera Pharmaceuticals to Host Conference Call and Webcast to Report First Quarter 2014 Financial Results and Provide a Detailed Pipeline Review

May 6, 2014 12:30 PM EDT

- Company to Review Pipeline of Orphan Therapeutic Candidates, Business Strategy and Recent Highlights -

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 6, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical stage biopharmaceutical company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, today announced that the Company will host a conference call and live audio webcast with an accompanying slide presentation at 8:00 a.m. EDT on Tuesday, May 13, 2014 to report its first quarter 2014 financial results. The Company will also provide a detailed review of its pipeline progress, business strategy, recent highlights and upcoming milestones.

In order to participate in the conference call, please dial 1-800-706-7741 (domestic) or 1-617-614-3471 (international) and provide the access code 15389137. The live webcast and slides can be accessed under "Investor Events" in the Investors section of the Company's website at www.iderapharma.com.

A replay of the call will be available at 1:30 p.m. EDT on May 13, 2014 until 11:59 p.m. EDT on May 20, 2014. To access the replay, please dial 1-888-286-8010 (domestic) or 1-617-801-6888 (international) and reference the access code 88784725. The archived webcast will be available for 30 days in the Investors section of Idera's website at www.iderapharma.com.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and orphan autoimmune diseases. Idera's proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like Receptors (TLRs). In addition to its TLR programs, Idera is developing gene silencing oligonucleotides (GSOs) that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA.

Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
larcudi@iderapharma.com
or
Stern Investor Relations, Inc.
Sarah McCabe, 212-362-1200
sarah@sternir.com